AstraZeneca in talks with Bristol Myers Squibb on $400 billion megadeal, FT reports
Who wants an AstraZeneca-Bristol Myers megadeal? Endpoints News Post-Hoc Live discusses the deal talks and organizes a live panel with industry experts to analyze motivations and feasibility.
Analysts and investors are skeptical, citing overlapping businesses and lack of clear strategic need, while the deal could create one of the world's largest pharma companies valued at nearly $400 billion.
The discussions are preliminary, no deal is certain, and neither company has confirmed or denied the talks publicly.
Sources:
AstraZeneca and Bristol Myers Squibb mull $400 billion deal
AstraZeneca and Bristol Myers Squibb mull $400 billion deal: Report
AstraZeneca held talks with Bristol Myers Squibb on $400 ...
AstraZeneca stock falls as investors balk at reported Bristol Myers tie-up
AstraZeneca falls to third-largest UK company amid US merger talks
AstraZeneca slides after reports of Bristol Myers merger ...
A $400 Billion AstraZeneca Deal Could Get Messy
AstraZeneca holds talks with Bristol Myers Squibb on $400 ...
Reuters on X: "AstraZeneca holds talks with Bristol Myers ...
Live today at 11 am ET: Who wants an AstraZeneca-Bristol ...
AstraZeneca investors balk at prospect of $400 billion ...